Antitumor activity of resveratrol PANC-1 (0.26106 cells mixed with Matrigel, Becton Dickinson, Bedford, MA) cells in a final volume of 0.1 ml were injected into the pancreas of Balb/c nu/nu mice (4–6 weeks old). The mice were purchased from the National Cancer Institute, Frederick, MD. After one week, mice (7 mice per group) were treated with resveratrol (0, 20, 40 and 60 mg/kg body weight) through gavage (Monday to Friday, 5 days a week for 6 weeks, once daily). At the end of the experiment, mice were euthanized as per approved protocol (The University of Texas Health Science Center at Tyler, Texas), and tumors were isolated and weighed. Immunohistochemistry Imunohistochemistry of pancreatic cancer cells, and tumor tissues collected on week 6 was performed as we described elsewhere [42]. TUNEL assays were performed as per manufac- turer’s instructions (Roche Applied Sciences). Statistical Analysis The mean and SD were calculated for each experimental group. Differences between groups were analyzed by one or two References 1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277–300. 2. Hruban RH (2001) Pancreatic cancer: from genes to patient care. J Gastrointest Surg 5: 583–587. 3. Li D (2001) Molecular epidemiology of pancreatic cancer. Cancer J 7: 259–265. 4. Gold EB, Goldin SB (1998) Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 7: 67–91. 5. Jaffee EM, Hruban RH, Canto M, Kern SE (2002) Focus on pancreas cancer. Cancer Cell 2: 25–28. 6. McKenna S, Eatock M (2003) The medical management of pancreatic cancer: a review. Oncologist 8: 149–160. 7. Shankar S, Singh G, Srivastava RK (2007) Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 12: 4839–4854. 8. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, et al. (2010) Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127: 257–268. 9. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, et al. (2011) Resveratrol inhibits pancreatic cancer stem cell characteristics in human and kras transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 6: e16530. 10. Anderson MJ, Viars CS, Czekay S, Cavenee WK, Arden KC (1998) Cloning and characterization of three human forkhead genes that comprise an FKHR- like gene subfamily. Genomics 47: 187–199. 11. Van Der Heide LP, Hoekman MF, Smidt MP (2004) The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 380: 297–309. 12. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, et al. (2000) Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20: 8969–8982. 13. Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, et al. (2002) FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol 156: 531–542. 14. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ (2003) Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110–2115. 15. Bokoch GM, Der CJ (1993) Emerging concepts in the Ras superfamily of GTP- binding proteins. Faseb J 7: 750–759. 16. Shih C, Weinberg RA (1982) Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29: 161–169. 17. Marshall MS (1995) Ras target proteins in eukaryotic cells. FASEB J 9: 1311–1318. 18. Schaeffer HJ, Weber MJ (1999) Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 19: 2435–2444. 19. Han J, Ulevitch RJ (1999) Emerging targets for anti-inflammatory therapy. Nat Cell Biol 1: E39–40. 20. Davis RJ (2000) Signal transduction by the JNK group of MAP kinases. Cell 103: 239–252. 21. Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180–186. FOXO-Dependent Regulation of Tumorigenesis way ANOVA, followed by Bonferoni’s multiple comparison tests using PRISM statistical analysis software (GrafPad Software, Inc., San Diego, CA). Significant differences among groups were calculated at P,0.05. Acknowledgments We thank our laboratory members for critical reading of the manuscript. We also thank Dr. Noboru Motoyama (National Institute for Longevity Sciences, Obu, Aichi, Japan) and Dr. Tatsuo Furuyama (Sonoda Women’s University, Amagasaki, Hyogo, Japan) for providing FOXO expression plasmids and FOXO-luciferase construct (pGL3-6X DBE), respectively. We thank Dr. William Sellers (Dana-Farber Cancer Institute, Boston, MA) for providing the PTEN-WT and AKT-DN expression vectors. Author Contributions Conceived and designed the experiments: SS RS. Performed the experiments: SR QC JF. Analyzed the data: QC JF. Contributed reagents/materials/analysis tools: SS RS. Wrote the paper: SS RS. 22. Kyriakis JM, Avruch J (1996) Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem 271: 24313–24316. 23. Lubinus M, Meier KE, Smith EA, Gause KC, LeRoy EC, et al. (1994) Independent effects of platelet-derived growth factor isoforms on mitogen- activated protein kinase activation and mitogenesis in human dermal fibroblasts. J Biol Chem 269: 9822–9825. 24. Shankar S, Chen Q, Srivastava RK (2008) Inhibition of PI3K/AKT and MEK/ ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal 3: 7. 25. Davis R, Singh KP, Kurzrock R, Shankar S (2009) Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep 22: 1473–1478. 26. Srivastava RK (2000) Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol Cell Biol Res Commun 4: 67–75. 27. Cappellini A, Tabellini G, Zweyer M, Bortul R, Tazzari PL, et al. (2003) The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia 17: 2157–2167. 28. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK (2010) Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 5: e15288. 29. Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13: 2905–2927. 30. Hutzen B, Willis W, Jones S, Cen L, Deangelis S, et al. (2009) Dietary agent, benzyl isothiocyanate inhibits signal transducer and activator of transcription 3 phosphorylation and collaborates with sulforaphane in the growth suppression of PANC-1 cancer cells. Cancer Cell Int 9: 24. 31. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, et al. (2008) Sulforaphane targets pancreatic tumor-initiating cells by NF-{kappa}B-induced anti-apoptotic signaling. Gut. 32. Shankar S, Ganapathy S, Srivastava RK (2007) Green tea polyphenols: biology and therapeutic implications in cancer. Front Biosci 12: 4881–4899. 33. Armour SM, Baur JA, Hsieh SN, Land-Bracha A, Thomas SM, et al. (2009) Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 1: 515–528. 34. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857–868. 35. Tang TT, Dowbenko D, Jackson A, Toney L, Lewin DA, et al. (2002) The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem 277: 14255–14265. 36. Shankar S, Ganapathy S, Hingorani SR, Srivastava RK (2008) EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 13: 440–452. 37. Srivastava RK, Unterman TG, Shankar S (2010) FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem 337: 201–212. 38. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, et al. (2006) Role of phosphatidylinositol 39-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108: 4178–4186. PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e25166